NIH Grand Rounds Interactive TV Series Will Premiere Next Year

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

BETHESDA, Md--A clinical education television series--Bench to Bedside--NIH Grand Rounds--is set to debut on January 15, 1997. Once a month, the world's leading clinicians from the various NIH institutes will discuss critical medical topics of the day.

BETHESDA, Md--A clinical education television series--Bench toBedside--NIH Grand Rounds--is set to debut on January 15, 1997.Once a month, the world's leading clinicians from the variousNIH institutes will discuss critical medical topics of the day.

The interactive program, sponsored by the NIH and CenterNet, thetelevision network of the Association of Academic Health Centers,will offer category 1 CME credit and will be made available toinstitutions outside of academic centers, including VA and communityhospitals.

For CenterNet subscription information, write: CenterNet, c/oHMTV, 1800 Diagonal Road, Suite 600, Alexandria, VA 22314 or callTom Shaw at 703-684-4415. The network can provide technical assistancefor institutions wishing to receive CenterNet programming.

Articles in this issue
Anesthetic Interventions Rise When Anesthesiologists Join the Pain Team
Worldwide UN Survey Shows Many Impediments to Morphine Availability
Case-Based Pain Curriculum Used in Canadian Schools
Effective Physician and Patient Communication Is Essential in Palliative Care
Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says
Brief Pain Inventory and Faces Scale Perform Well in a Group of Low-Income, Primarily Black Cancer Patients
Whole-Body Vibration Within Specified Frequency Range May Provide Pain Relief
Pain Descriptions May Predict Presence of Neuropathic Pain
Neurotoxicity Related to High-Dose Opioid Therapy Can Be Managed
Epidural Morphine Relieves Pain in Advanced Cancer, But May Not Influence Quality of Life
Dr. Payne Urges Strategies to Overcome Barriers to Use of Cancer Pain Guidelines
Program Trains Community Opinion Leaders in Principles of Pain Control
Postmarketing Surveillance for Drug Abuse Supports Nonscheduled Status of Tramadol
Consider Quality of Life and Patient Preference When Choosing Pain Relief
Patients' Pain Anxiety Levels Vary Depending on the Type of Pain, the Patient's Gender, and Pain Duration
Related Videos
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, experts on colorectal cancer
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, experts on colorectal cancer
Experts on MM
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer
Related Content
Exercise May Mitigate Chemo-Induced Peripheral Neuropathy in Ovarian Cancer | Image Credit: © Lars Neumann - stock.adobe.com.

Exercise May Mitigate Chemo-Induced Peripheral Neuropathy in Ovarian Cancer

December 5th 2023
Article

Implementing exercise programs into standard oncology care may help improve quality of life for patients with ovarian cancer.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL

December 4th 2023
Article

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.

UGN-102 Yields Complete Responses in Non-Muscle Invasive Bladder Cancer

December 4th 2023
Article

If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.

Site Logo

Resectable NSCLC: Surgeon & Oncologist Perspectives on Neoadjuvant Therapy

December 4th 2023
Article